Similar articles

• Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease?

  Cesari M, Pavan E, Sacchetto A, Rossi GP. Cesari M, et al. Am Heart J. 1996 Dec;132(6):1236-43. doi: 10.1016/s0002-8703(96)90468-8. Am Heart J. 1996. PMID: 8969576 Review.
• Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).

  O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Frey A, Gheorghiade M; Randomized Intravenous Tezosentan Study Investigators. O'Connor CM, et al. Am Heart J. 2003 Feb;145(2 Suppl):S58-9. doi: 10.1067/mhj.2003.156. Am Heart J. 2003. PMID: 12594454 Clinical Trial. No abstract available.
• Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

  Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Bliden KP, et al. J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. doi: 10.1016/j.jacc.2006.10.050. Epub 2007 Jan 26. J Am Coll Cardiol. 2007. PMID: 17291930
• Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart.

  Wang P, Gallagher KP, Downey JM, Cohen MV. Wang P, et al. J Mol Cell Cardiol. 1996 Mar;28(3):579-88. doi: 10.1006/jmcc.1996.0054. J Mol Cell Cardiol. 1996. PMID: 9011641
• The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.

  Gurbel PA. Gurbel PA. Rev Cardiovasc Med. 2006;7 Suppl 4:S20-8. Rev Cardiovasc Med. 2006. PMID: 17224887 Review.